WO2024141784 - BROADLY PROTECTIVE BETACORONAVIRUS VACCINES AND COMPOSITIONS
National phase entry is expected:
Publication Number
WO/2024/141784
Publication Date
04.07.2024
International Application No.
PCT/IB2023/000780
International Filing Date
28.12.2023
Title **
[English]
BROADLY PROTECTIVE BETACORONAVIRUS VACCINES AND COMPOSITIONS
[French]
VACCINS ET COMPOSITIONS À PROTECTION LARGE CONTRE LES BÈTACORONAVIRUS
Applicants **
POPVAX PRIVATE LIMITED
Inventors
MOHARANA, Tushar, Ranjan
SANKARAN, Soham, Govindarajan
Priority Data
63/435,980
29.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3691 | |
| EPO | Filing, Examination, Granting | 45350 | |
| Japan | Filing, Examination, Granting | 3744 | |
| South Korea | Filing, Examination, Granting | 5011 | |
| USA | Filing, Examination, Granting | 17740 |
Total:
75,536
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates generally to nucleic acids encoding a polypeptide. The polypeptide comprises a receptor binding domain (RBD), a fusion peptide, or a stem helix, or a combination thereof. The RBD, the fusion peptide, or the stem helix is obtained or derived from a betacoronavirus.[French]
La présente invention concerne de manière générale des acides nucléiques codant pour un polypeptide. Le polypeptide comprend un domaine de liaison de récepteur (RBD), un peptide de fusion ou une hélice à tige, ou une combinaison de ceux-ci. Le RBD, le peptide de fusion ou l'hélice à tige sont obtenus ou dérivés d'un bêtacoronavirus.